Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genmab | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 86.87B | 18.7x | 1.3 | DKK 1,369.50 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zealand Pharma | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 51.40B | -43.7x | 2.98 | DKK 727 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.7% Upside | Upgrade to Pro+ | |
Gubra AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 10.24B | -249.6x | 0.53 | DKK 630 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ViroGates | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 95.91M | -6.1x | -0.21 | DKK 12.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Strategic Partners AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 32.99M | -2.5x | -0.04 | DKK 790.90 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |